Subtype-Specific Breast Cancer Incidence Rates in Black versus White Men in the United States.
Journal
JNCI cancer spectrum
ISSN: 2515-5091
Titre abrégé: JNCI Cancer Spectr
Pays: England
ID NLM: 101721827
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
08
08
2019
revised:
07
10
2019
accepted:
01
11
2019
entrez:
28
4
2020
pubmed:
28
4
2020
medline:
28
4
2020
Statut:
epublish
Résumé
Compared with white women, black women have higher incidence rates for triple-negative breast cancer but lower rates for hormone receptor (HR)-positive cancers in the United States. Whether similar racial difference occurs in male breast cancer is unclear. We examined racial differences in incidence rates of breast cancer subtypes defined by HR and human epidermal growth factor receptor 2 (HER2) by sex using nationwide data from 2010 to 2016. Among men, rates were higher in blacks than whites for all subtypes, with the black-to-white incidence rate ratios of 1.41 (95% confidence interval [CI ]= 1.32 to 1.50) for HR+/HER-, 1.65 (95% CI = 1.40 to 1.93) for HR+/HER2+, 2.62 (95% CI = 1.48 to 4.43) for HR-/HER2+, and 2.27 (95% CI = 1.67 to 3.03) for triple-negative subtype. Conversely, among women, rates in blacks were 21% lower for HR+/HER2- and comparable for HR+/HER2+ but 29% and 93% higher for HR-/HER2+ and triple-negative subtypes, respectively. Future studies are needed to identify contributing factors to the dissimilar racial patterns in breast cancer subtype incidence between men and women.
Identifiants
pubmed: 32337499
doi: 10.1093/jncics/pkz091
pii: pkz091
pmc: PMC7050146
doi:
Types de publication
Journal Article
Langues
eng
Pagination
pkz091Informations de copyright
© The Author(s) 2020. Published by Oxford University Press.
Références
J Natl Cancer Inst. 2015 Mar 30;107(6):djv048
pubmed: 25825511
J Natl Cancer Inst. 2014 Mar;106(3):djt465
pubmed: 24552677
N Engl J Med. 2018 Jun 14;378(24):2311-2320
pubmed: 29897847
CA Cancer J Clin. 2019 May;69(3):211-233
pubmed: 30762872
J Clin Oncol. 2015 Jun 20;33(18):2041-50
pubmed: 25964249
J Natl Cancer Inst. 2008 Oct 15;100(20):1477-81
pubmed: 18840816
J Natl Cancer Inst. 2013 Sep 18;105(18):1365-72
pubmed: 24003037
J Natl Cancer Inst. 2014 Apr 28;106(5):
pubmed: 24777111
Eur J Cancer. 2015 Nov;51(16):2289-95
pubmed: 26248686
Nat Genet. 2012 Nov;44(11):1182-4
pubmed: 23001122
Cancer Causes Control. 2006 Mar;17(2):127-36
pubmed: 16425090
PLoS Genet. 2011 Sep;7(9):e1002290
pubmed: 21949660
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
CA Cancer J Clin. 2017 Nov;67(6):439-448
pubmed: 28972651